原发性骨髓纤维化患者CD 34^+细胞水平变化及临床意义

The Change and Clinical Impact of Primary Myelofivrosis Patients With CD 34^+ Cell Level

目的探讨原发性骨髓纤维化患者外周血中CD 34+细胞水平变化及临床意义。方法选取我科收治的15例原发性骨髓纤维化患者作为观察组,15例健康志愿者作为对照组,运用免疫组织化学染色法检测两组人群外周血中CD 34+细胞百分比及单核细胞计数,比较两组数据差异。结果原发性骨髓纤维化患者外周血中CD 34+细胞计数较对照组高,P<0.05,差异具有统计学意义。结论原发性骨髓纤维化患者外周血中CD 34+细胞数量较健康人高,可作为骨髓纤维化疾病的鉴别、诊断和病情预测标准,指导临床治疗方案的制定。

Objective To investigate clinical significance of the changes of CD 34＋cells in peripheral blood of patients with primary bone marrow ifbrosis.Methods Selected 15 patients with primary bone marrow ifbrosis as observation group and 15 healthy volunteers as control group, The percentage of CD 34＋cells in the peripheral blood of the two groups were detected by used immunohistochemical staining method, and the data were compared between the two groups.Results CD 34＋ cell count in peripheral blood of patients with primary bone marrow fibrosis was higher than he control group,P〈0.05, had difference statistically signiifcance.Conclusion The number of CD 34＋ cells in peripheral blood of patients with primary bone marrow ifbrosis is higher than that of healthy people, which can be used as the standard of diagnosis, diagnosis and prognosis of the disease.